Medicine and Dentistry
Patient
100%
Chemotherapy
41%
Breast Cancer
38%
Inpatient
31%
Metastatic Breast Cancer
20%
Overall Survival
19%
Malignant Neoplasm
19%
Neoplasm
18%
Neoadjuvant Chemotherapy
17%
Survival
15%
Colorectal Cancer
12%
Progression Free Survival
11%
Hormone Receptor
11%
Association
10%
Body Mass Index
9%
Biliary Tract Cancer
9%
Pancreas Cancer
9%
Analysis
8%
Woman
8%
Irinotecan
7%
Disease Free Survival
7%
Surgery
7%
Recurrent Disease
7%
Oxaliplatin
7%
Lesion
7%
Gamma Urogastrone
6%
Triple Negative Breast Cancer
6%
Gemcitabine
6%
Metastatic Colorectal Cancer
6%
Epidermal Growth Factor Receptor 2
6%
Disease
6%
Prognosis
6%
Age
6%
Hazard Ratio
6%
Protein Expression
6%
Paclitaxel
5%
Microsatellite Instability
5%
Evaluation Study
5%
Prognostic Factor
5%
Biological Marker
5%
Patient with Cancer
5%
Arm
5%
Serum
5%
Toxicity
5%
Combination Therapy
5%
Phenotype
5%
Lymphocyte
5%
Neutrophil
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
33%
Breast Cancer
27%
Stomach Cancer
23%
Overall Survival
19%
Metastatic Breast Cancer
18%
Neoplasm
15%
Progression Free Survival
13%
Malignant Neoplasm
13%
Survival
10%
Oxaliplatin
10%
Trastuzumab
9%
Biliary Tract Cancer
9%
Fluorouracil
8%
Paclitaxel
8%
Irinotecan
8%
Gemcitabine
8%
Toxicity
7%
Gamma Urogastrone
7%
Epidermal Growth Factor Receptor 2
7%
Hormone Receptor
7%
Diseases
6%
Pancreas Cancer
6%
Biological Marker
6%
Prognosis
5%
Colorectal Cancer
5%
Liver Cell Carcinoma
5%
Metastatic Colorectal Cancer
5%
Adverse Event
5%